MedDataX Logo

UK Study Assessing Flexible Dose Fesoterodine in Adults

NCT ID: NCT00806494

Last Updated: 2011-01-26

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

331 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-02-28

Study Completion Date

2010-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To explore the effects of fesoterodine when used in a flexible dose manner

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Fesoterodine Flexible Dose Study

NCT00536484

Overactive Bladder
COMPLETED PHASE3

Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder.

NCT00658684

Overactive Bladder
COMPLETED PHASE3

A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.

NCT00798434

Urinary Bladder, Overactive
COMPLETED PHASE4

Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.

NCT00561951

Overactive Bladder
COMPLETED PHASE2

A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency

NCT00911937

Overactive Bladder
COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urinary Bladder, Overactive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment Arm

Fesoterodine 4mg, escalating to 8mg as required

Group Type EXPERIMENTAL

Fesoterodine

Intervention Type DRUG

Fesoterodine 4mg for 4 weeks, escalating to fesoterodine 8mg if tolerated

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fesoterodine

Fesoterodine 4mg for 4 weeks, escalating to fesoterodine 8mg if tolerated

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female \>18 years old
* OAB for \>3 months

Exclusion Criteria

* Patients with conditions that would contraindicate for fesoterodine use
* Patients with significant hepatic and renal disease or other significant unstable diseases.
* OAB symptoms caused by neurological conditions, known pathologies of urinary tract, etc.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Pfizer, Inc.

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Ely, Cambridgeshire, United Kingdom

Site Status

Pfizer Investigational Site

Crewe, Cheshire, United Kingdom

Site Status

Pfizer Investigational Site

Fowey, Cornwall, United Kingdom

Site Status

Pfizer Investigational Site

Penzance, Cornwall, United Kingdom

Site Status

Pfizer Investigational Site

Chesterfield, Derbyshire, United Kingdom

Site Status

Pfizer Investigational Site

Chesterfield, Derbyshire, United Kingdom

Site Status

Pfizer Investigational Site

Plymouth, Devon, United Kingdom

Site Status

Pfizer Investigational Site

Bexhill-on-Sea, East Sussex, United Kingdom

Site Status

Pfizer Investigational Site

Baillieston, Glasgow, United Kingdom

Site Status

Pfizer Investigational Site

Blackpool, Lancashire, United Kingdom

Site Status

Pfizer Investigational Site

Blackpool, Lancashire, United Kingdom

Site Status

Pfizer Investigational Site

Hinckley, Leicestershire, United Kingdom

Site Status

Pfizer Investigational Site

West Didsbury, Manchester, United Kingdom

Site Status

Pfizer Investigational Site

Ashford, Middlesex, United Kingdom

Site Status

Pfizer Investigational Site

Northwood, Middlesex, United Kingdom

Site Status

Pfizer Investigational Site

Mortimer, Reading, United Kingdom

Site Status

Pfizer Investigational Site

Ayrshire, Scotland, United Kingdom

Site Status

Pfizer Investigational Site

Falkirk, Scotland, United Kingdom

Site Status

Pfizer Investigational Site

Winterton, Scunthorpe, United Kingdom

Site Status

Pfizer Investigational Site

Bath, Somerset, United Kingdom

Site Status

Pfizer Investigational Site

Doncaster, South Yorkshire, United Kingdom

Site Status

Pfizer Investigational Site

Sheffield, South Yorkshire, United Kingdom

Site Status

Pfizer Investigational Site

Addlestone, Surrey, United Kingdom

Site Status

Pfizer Investigational Site

Leatherhead, Surrey, United Kingdom

Site Status

Pfizer Investigational Site

Worthing, West Sussex, United Kingdom

Site Status

Pfizer Investigational Site

Bradford-on-Avon, Wiltshire, United Kingdom

Site Status

Pfizer Investigational Site

Chippenham, Wilts, United Kingdom

Site Status

Pfizer Investigational Site

Bath, , United Kingdom

Site Status

Pfizer Investigational Site

Bath, , United Kingdom

Site Status

Pfizer Investigational Site

Bristol, , United Kingdom

Site Status

Pfizer Investigational Site

Bucks, , United Kingdom

Site Status

Pfizer Investigational Site

Glasgow, , United Kingdom

Site Status

Pfizer Investigational Site

Hertfordshire, , United Kingdom

Site Status

Pfizer Investigational Site

London, , United Kingdom

Site Status

Pfizer Investigational Site

London, , United Kingdom

Site Status

Pfizer Investigational Site

Northants, , United Kingdom

Site Status

Pfizer Investigational Site

Plymouth, , United Kingdom

Site Status

Pfizer Investigational Site

Swansea, , United Kingdom

Site Status

Pfizer Investigational Site

Swindon, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Related Links

Access external resources that provide additional context or updates about the study.

https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0221058&StudyName=UK%20Study%20Assessing%20Flexible%20Dose%20Fesoterodine%20in%20Adults%20

To obtain contact information for a study center near you, click here.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A0221058

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder
NCT00928070 COMPLETED PHASE4
A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients
NCT00425100 COMPLETED PHASE3
A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.
NCT01302054 COMPLETED PHASE4
Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.
NCT00611026 COMPLETED PHASE3
Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)
NCT00444925 COMPLETED PHASE3
A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine
NCT01302067 COMPLETED PHASE4
A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome
NCT00220363 COMPLETED PHASE3
A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition
NCT01557244 COMPLETED PHASE3
Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years
NCT00857896 COMPLETED PHASE2
Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome
NCT00138723 COMPLETED PHASE3
This Is A Study Of Bioavailability And Food Effect For Fesoterodine.
NCT01286454 COMPLETED PHASE1
Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients With Overactive Bladder
NCT01054222 COMPLETED PHASE4
Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome
NCT00220402 COMPLETED PHASE3
Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children.
NCT02614482 COMPLETED PHASE3
Evaluation Of The Ability Of Fesoterodine To Increase Urethral Pressure In Stress Urinary Incontinence Patients
NCT01042236 COMPLETED PHASE2
Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.
NCT02501928 COMPLETED PHASE3
This Is An Open-Label Study To Evaluate Fesoterodine Plus "Your Way" Patient Support Plan In Patients With Symptoms Of Overactive Bladder
NCT00943735 COMPLETED
Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome
NCT00220376 COMPLETED PHASE3
Fesoterodine "add-on" Male Overactive Bladder Study
NCT00546637 COMPLETED PHASE3
A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment
NCT02240459 COMPLETED PHASE2
Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase
NCT00220389 COMPLETED PHASE2
Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children
NCT02327936 COMPLETED PHASE3
Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive Bladder
NCT01578304 COMPLETED PHASE4
Fall Prevention in Older Adults With OAB
NCT03946124 COMPLETED PHASE4
Post Marketing Surveillance Of Fesoterodine In Filipino Patients With Over Active Bladder
NCT01260311 COMPLETED